Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Catalent stock (CTLT)

Buy Catalent stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Catalent is a drug manufacturers - specialty & generic business based in the US. Catalent shares (CTLT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $63.48 – an increase of 0.65% over the previous week. Catalent employs 17,000 staff and has a trailing 12-month revenue of around $4.4 billion.

Our top picks for where to buy Catalent stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for stock bonuses

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you fund a new account within 30 days
  • Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%

How to buy Catalent stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CTLT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Catalent stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Product USFST Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Finder score
Stocks, ETFs
$0
$0
N/A
Earn up to $300
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Finder score
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Catalent stock price (NYSE: CTLT)

Use our graph to track the performance of CTLT stocks over time.

Catalent shares at a glance

Information last updated 2024-12-19.
Latest market close$63.48
52-week range$42.11 - $63.50
50-day moving average $60.41
200-day moving average $58.20
Wall St. target price$63.40
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-2.28

Is it a good time to buy Catalent stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalent price performance over time

Historical closes compared with the close of $63.48 from 2024-12-17

1 week (2024-12-13) 0.65%
1 month (2024-11-21) 6.40%
3 months (2024-09-20) 5.80%
6 months (2024-06-21) 12.35%
1 year (2023-12-21) 44.60%
2 years (2022-12-21) 46.10%
3 years (2021-12-21) 124.53
5 years (2019-12-20) 14.25%

Is Catalent stock undervalued or overvalued?

Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalent's PEG ratio

Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 529. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalent's EBITDA

Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $462 million.

The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.

Catalent financials

Revenue TTM $4.4 billion
Gross profit TTM $1 billion
Return on assets TTM -0.18%
Return on equity TTM -11.19%
Profit margin -9.34%
Book value $19.52
Market Capitalization $11.5 billion

TTM: trailing 12 months

Catalent share dividends

We're not expecting Catalent to pay a dividend over the next 12 months.

Catalent share price volatility

Over the last 12 months, Catalent's shares have ranged in value from as little as $42.11 up to $63.5. A popular way to gauge a stock's volatility is its "beta".

CTLT.US volatility(beta: 1.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.158. This would suggest that Catalent's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Catalent overview

Catalent, Inc. , together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions.

Frequently asked questions

null
What percentage of Catalent is owned by insiders or institutions?
Currently 0.502% of Catalent shares are held by insiders and 87.87% by institutions.
How many people work for Catalent?
Latest data suggests 17,000 work at Catalent.
When does the fiscal year end for Catalent?
Catalent's fiscal year ends in June.
Where is Catalent based?
Catalent's address is: 14 Schoolhouse Road, Somerset, NJ, United States, 08873
What is Catalent's ISIN number?
Catalent's international securities identification number is: US1488061029
What is Catalent's CUSIP number?
Catalent's Committee on Uniform Securities Identification Procedures number is: 148806102

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site